{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:56:38Z","timestamp":1769601398850,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To compare the short-term tumor response and long-term clinical outcome of two preoperative chemoradiotherapy (CRT) regimens for locally advanced rectal cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study included 231 patients scheduled for preoperative CRT using two chemotherapeutic protocols from April 2003\u2013August 2006. Pelvic radiotherapy (50.4\u00a0Gy) was delivered concurrently with capecitabine (<jats:italic>n<\/jats:italic>\u2009=\u2009148) or capecitabine\/irinotecan (<jats:italic>n\u2009=<\/jats:italic>\u200983). Surgery was performed 4\u20138\u00a0weeks after CRT completion. Tumor responses to CRT were assessed using both radiologic and pathologic measurements. Radiologic responses were evaluated by magnetic resonance volumetry, which was performed at the initial work-up and after completion of preoperative CRT just before surgery. Pathologic responses were assessed with downstaging (ypStage 0-1) and grading tumor regression. Clinical outcomes were evaluated in terms of local control, relapse-free survival, and overall survival rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Radiologic examination demonstrated that tumor volume decreased by 65.6% in the capecitabine group and 66.8% capecitabine\/irinotecan group (<jats:italic>p<\/jats:italic>\u2009=\u20090.731). Postoperative pathologic stage determination showed that tumor downstaging occurred in 44.1% of the capecitabine group and 48.6% of the capecitabine\/irinotecan group (<jats:italic>p<\/jats:italic>\u2009=\u20090.538). The sum of tumor regression grade 3 (near complete response) and 4 (complete response) after CRT were 28.6% in the capecitabine group and 37.5% in the capecitabine\/irinotecan group (<jats:italic>p<\/jats:italic>\u2009=\u20090.247). There were no significant differences between the two groups in 5-year local control (91.7% <jats:italic>vs.<\/jats:italic> 92.5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.875), relapse-free survival (80.8% <jats:italic>vs.<\/jats:italic> 77.2%; <jats:italic>p<\/jats:italic>\u2009=\u20090.685), and overall survival (88.4% <jats:italic>vs.<\/jats:italic> 90.4%; <jats:italic>p<\/jats:italic>\u2009=\u20090.723).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study revealed no differences in the short-term tumor response and long-term clinical outcome between preoperative capecitabine and capecitabine\/irinotecan CRT regimens for locally advanced rectal cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1748-717x-8-258","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T12:01:16Z","timestamp":1383566476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan"],"prefix":"10.1186","volume":"8","author":[{"given":"Sung Uk","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yeon","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hwan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,4]]},"reference":[{"key":"979_CR1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J med 2004, 351: 1731-1740. 10.1056\/NEJMoa040694","journal-title":"N Engl J med"},{"key":"979_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijrobp.2006.08.063","volume":"67","author":"DY Kim","year":"2007","unstructured":"Kim DY, Jung KH, Kim TH, Kim DW, Chang HJ, Jeong JY, Kim YH, Son SH, Yun T, Hong CW, et al.: Comparison of 5-fluorouracil\/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol 2007, 67: 378-384. 10.1016\/j.ijrobp.2006.08.063","journal-title":"Int J Radiat Oncol Biol"},{"key":"979_CR3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Canc 1998, 34: 1274-1281. 10.1016\/S0959-8049(98)00058-6","journal-title":"Eur J Canc"},{"key":"979_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Muller L, Link H, Moehler M, Kettner E, et al.: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012, 13: 579-588. 10.1016\/S1470-2045(12)70116-X","journal-title":"Lancet Oncol"},{"key":"979_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343: 905-914. 10.1056\/NEJM200009283431302","journal-title":"N Engl J Med"},{"key":"979_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.2005.04.171","volume":"23","author":"RD Hofheinz","year":"2005","unstructured":"Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Muldner A, Hehlmann R, Post S, Hochhaus A, Willeke F: Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005, 23: 1350-1357. 10.1200\/JCO.2005.04.171","journal-title":"J Clin Oncol"},{"key":"979_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ijrobp.2009.12.073","volume":"79","author":"YS Hong","year":"2011","unstructured":"Hong YS, Kim DY, Lim SB, Choi HS, Jeong SY, Jeong JY, Sohn DK, Kim DH, Chang HJ, Park JG, Jung KH: Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study. Int J Radiat Oncol Biol 2011, 79: 1171-1178. 10.1016\/j.ijrobp.2009.12.073","journal-title":"Int J Radiat Oncol Biol"},{"key":"979_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Canc Inst 2000, 92: 205-216. 10.1093\/jnci\/92.3.205","journal-title":"J Natl Canc Inst"},{"key":"979_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"American Joint Committee on Cancer staging manual","author":"FL Green","year":"2002","unstructured":"Green FL, Page DL, Fleming ID: American Joint Committee on Cancer staging manual. 6th edition. Philadelphia: Springer; 2002.","edition":"6"},{"key":"979_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12: 19-23. 10.1007\/s003840050072","journal-title":"Int J Colorectal Dis"},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejso.2004.11.011","volume":"31","author":"SB Lim","year":"2005","unstructured":"Lim SB, Heo S, Lee M, Kang SB, Park Y, Park K, Choi H, Jeong SY, Park JG: Changes in outcome with sphincter preserving surgery for rectal cancer in Korea, 1991\u20132000. Eur J Surg Oncol 2005, 31: 242-249. 10.1016\/j.ejso.2004.11.011","journal-title":"Eur J Surg Oncol"},{"key":"979_CR12","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1200\/JCO.2004.08.009","volume":"22","author":"TA Rich","year":"2004","unstructured":"Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004, 22: 2214-2232. 10.1200\/JCO.2004.08.009","journal-title":"J Clin Oncol"},{"key":"979_CR13","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352: 2696-2704. 10.1056\/NEJMoa043116","journal-title":"N Engl J Med"},{"key":"979_CR14","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18: 2938-2947.","journal-title":"J Clin Oncol"},{"key":"979_CR15","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP G\u00e9rard","year":"2010","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Fran\u00e7ois E, de La Roche G, Bouch\u00e9 O: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol 2010, 28: 1638-1644. 10.1200\/JCO.2009.25.8376","journal-title":"J Clin Oncol"},{"key":"979_CR16","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2011.35.7301","volume":"29","author":"M Roh","year":"2011","unstructured":"Roh M, Yothers G, O\u2019Connell M, Beart R, Pitot H, Shields A, Parda D, Sharif S, Allegra C, Petrelli N: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011, 29: 3503. 10.1200\/JCO.2011.35.7301","journal-title":"J Clin Oncol"},{"key":"979_CR17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/sj.bjc.6603645","volume":"96","author":"F Willeke","year":"2007","unstructured":"Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, K\u00e4hler G, Post S: A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Canc 2007, 96: 912-917. 10.1038\/sj.bjc.6603645","journal-title":"Br J Canc"},{"key":"979_CR18","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/j.ijrobp.2011.03.022","volume":"82","author":"SG Yeo","year":"2012","unstructured":"Yeo SG, Kim DY, Park JW, Oh JH, Kim SY, Chang HJ, Kim TH, Kim BC, Sohn DK, Kim MJ: Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer. Int J Radiat Oncol Biol 2012, 82: e193-e199. 10.1016\/j.ijrobp.2011.03.022","journal-title":"Int J Radiat Oncol Biol"},{"key":"979_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijrobp.2009.07.1682","volume":"78","author":"S-G Yeo","year":"2010","unstructured":"Yeo S-G, Kim DY, Kim TH, Jung KH, Hong YS, Chang HJ, Park JW, Lim S-B, Choi HS, Jeong S-Y: Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol 2010, 78: 164-171. 10.1016\/j.ijrobp.2009.07.1682","journal-title":"Int J Radiat Oncol Biol"},{"key":"979_CR20","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1002\/cncr.27507","volume":"118","author":"SH Moon","year":"2012","unstructured":"Moon SH, Kim DY, Park JW, Oh JH, Chang HJ, Kim SY, Kim TH, Park HC, Choi DH, Chun HK, et al.: Can the new American joint committee on cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy? Cancer 2012, 118: 4961-4968. 10.1002\/cncr.27507","journal-title":"Cancer"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-8-258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:04:52Z","timestamp":1630548292000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/1748-717X-8-258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1186\/1748-717x-8-258","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,4]]},"assertion":[{"value":"17 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"258"}}